These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 29547895)

  • 1. Gout: state of the art after a decade of developments.
    Pascart T; Lioté F
    Rheumatology (Oxford); 2019 Jan; 58(1):27-44. PubMed ID: 29547895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future therapies for gout.
    Pascart T; Richette P
    Expert Opin Pharmacother; 2017 Aug; 18(12):1201-1211. PubMed ID: 28689430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.
    So MW; Kim AR; Lee SG
    Int J Rheum Dis; 2023 Sep; 26(9):1770-1778. PubMed ID: 37431263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3.
    Novella-Navarro M; Cabrera-Alarcon JL; Diaz-Torne C; Aramburu-Muñoz F; Janta I; Ortega de la O MC; Prada-Ojeda A; Sala-Icardo L; Urruticoechea-Arana A; García de la Peña Lefebvre P; Calvo-Aranda E
    Rheumatol Int; 2020 Jul; 40(7):1081-1087. PubMed ID: 31982955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
    Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
    Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gout management: an update].
    Ankli B; Krähenbühl S
    Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
    Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
    Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
    Soskind R; Abazia DT; Bridgeman MB
    Expert Opin Pharmacother; 2017 Aug; 18(11):1115-1125. PubMed ID: 28658988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
    Keenan RT
    Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febuxostat: a new treatment for hyperuricaemia in gout.
    Edwards NL
    Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febuxostat.
    Hair PI; McCormack PL; Keating GM
    Drugs; 2008; 68(13):1865-74. PubMed ID: 18729537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of treatment of hyperuricemic in patients admitted to the rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines.
    Banse C; Fardellone P; Paccou J
    Joint Bone Spine; 2014 Oct; 81(5):461-2. PubMed ID: 24703403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.